A New COVID-19 Breakthrough?
As COVID-19 has spread across the globe, taking over 2 million lives over the last year, help may be coming from an unexpected place.
While some are unconcerned with the mortality rate of the virus at roughly 1-2% for the general population…
The virus can be particularly dangerous for one population.
For those with a history of cardiovascular issues, the survival rate plummets down to nearly 50%.
Reference: Shaobo Shi et al., ‘Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China’, JAMA Cardiology, 25 March 2020
That’s because as the immune system works to fight the virus, in some cases it can end up attacking the essential body organs themselves…
And for those who have suffered from issues with the heart and lungs before, it can cause deadly complications with the organs that aren’t working at full strength.
But one company, Cardiol Therapeutics, may have a solution that could help save lives around the world.
The company is working with cannabidiol (CBD), a molecule that has already been proven helpful in treating other diseases, like certain types of childhood epilepsy.
And with Big Pharma recently making a massive acquisition of another company working with CBD…
They’ve put their stamp of approval on this revolutionary treatment and put its value in the billions of dollars.
David Johnson, chief executive of Enveric Biosciences Inc. stated the deal “serves as further validation that thoroughly researched and developed medical cannabinoids have significant potential to address patients’ unmet medical needs.”
DOWNLOAD OUR SPECIAL REPORT ON CARDIOL’S REVOLUTIONARY TREATMENT AND HOW EARLY INVESTORS COULD PROFIT.
In the case of COVID-19, this molecule may prove to have protective benefits for the heart as well.
That means protecting the lining of blood vessels and the heart muscle from inflammation… Helping the heart pump blood more effectively… And even reducing scarring in the heart and lungs.
The rationale for using cannabidiol to treat patients with COVID-19 is based on extensive pre-clinical investigations by Cardiol and others in models of cardiovascular inflammation.
These investigations have demonstrated that CBD has impressive anti-inflammatory and anti-fibrotic activity.
With CBD’s excellent safety profile, most notably in children, Cardiol has been given the green light from the FDA to start a Phase II/Phase III trial shortly for their oral CBD formulation, CardiolRx™.
Any news of positive results as the trial progresses could be a game-changer for this company with a market cap just over USD$100 million.
After all, biotech giants like Regeneron and Eli Lilly have made headlines for their efforts in producing an effective COVID-19 treatment…
Including when Regeneron’s antibody treatment was given to President Trump at the Walter Reed Medical Center last year when he contracted the virus.
But while these companies have focused on treating the disease more generally…
Cardiol may have a treatment that would be geared specifically to the most vulnerable population, which could potentially save the lives of those who need it most.
And this could be a significant development used for years to come.
Regardless of how effective the COVID-19 vaccines prove to be, many are expecting we’ll see the virus occur seasonally for many years, much like the flu season we deal with every winter.
Particularly during a year where we’re still scrambling to get a handle on the virus, analysts are very bullish on Cardiol’s future.
That means that with its shares currently trading at just over USD$3, Cardiol could produce significant returns for early investors ahead of these important trials.
But while many are excited about the upcoming COVID-19 trials, Cardiol has a number of other treatments that could be life-changing.
Much More in the Pipeline
While much of the focus recently has been on the urgent need for COVID-19 treatments, Cardiol has also been hard at work applying their CardiolRx™ to other conditions.
At the moment, they’re also planning to file with the FDA to begin a Phase II international trial for a major cause of sudden cardiac death in children and young adults.
This disease, acute myocarditis, is the most common cause of sudden cardiac death in people less than 35 years old, affecting 73,000 young Americans today.
If results of this trial are positive, it could not only deliver hope to tens of thousands, it could also prove to be lucrative for Cardiol.
Through the FDA’s Orphan Drug Designation program, an orphan drug status is granted for pharmaceuticals being developed to treat medical conditions affecting fewer than 200,000 people.
This program offers biotech companies a host of benefits as motivation to develop treatments for rare diseases affecting thousands.
And going down this path has helped a number of small biotech companies turn into billion-dollar giants in a very short window of time.
This was the case for GW Pharmaceuticals, who built a multi-billion dollar enterprise over just 3 1/2 years for their cannabidiol treatment for two rare forms of childhood epilepsy.
Since then, they have added an indication for using CBD for TSC associated seizures.
And just recently, Jazz Pharmaceuticals announced that they’re set to acquire GW Pharma for an incredible USD$7.2 billion.
Jason Wilson, banking expert at ETF Managers Group touted, “The deal is a clear sign that the pharmaceutical industry is recognizing the value and future potential of cannabinoid-based medicines.”
But Cardiol is aiming to treat a patient group that’s twice the size of these two rare childhood epilepsy markets, and they’re very hopeful about their prospects in upcoming trials.
That’s because past research has shown the dramatic effects of this molecule.
But while they’ve been busy preparing for these two clinical trials, they’ve also been making strides in the massive market for chronic heart failure.
As the single biggest cause of hospitalizations in the U.S., heart failure takes a huge toll on the healthcare system, with costs exceeding USD$30 billion each year.
And with over 6 million adults in North America suffering from heart failure, sadly, 30% of patients with heart failure die within 1 year.
There’s been shockingly little development in treatment advances for diastolic heart failure in over 20 years.
That is, until Cardiol started developing a proprietary subcutaneous formulation of CardiolRx™, administered the same way insulin is for diabetes.
This subcutaneous formulation would be a new approach to the treatment of chronic heart failure based on the anti-inflammatory activity of cannabidiol to treat inflamed heart tissue and the anti-fibrotic activity of cannabidiol to treat fibrosis (scarring) in heart muscle.
It could be the breakthrough that millions of people have been waiting for.
While still at an early stage, this could have tremendous implications for an enormous market.
But in the meantime, Cardiol has found a way to drive revenue even before starting clinical trials thanks to a new partnership in Canada.
The cannabidiol molecule, also known as CBD, has already proven to be effective in treating rare types of childhood epilepsy.
And many providers are demanding a cannabidiol solution that does not contain Tetrahydrocannabinol (THC), the active psychoactive ingredient in cannabis.
Cardiol has produced the purest form of an oral cannabidiol formulation to date, Cortalex™, holding their product to the highest standards in the industry.
And they just partnered with Shoppers Drug Mart, the largest pharmacy chain in Canada, with over 1,300 stores, to supply it.
Cortalex is now available across Canada exclusively at Medical Cannabis by Shoppers™ online portal, a subsidiary of Shoppers Drug Mart.
The medicinal cannabinoid market in Canada is estimated to be over USD$600 million and is projected to be worth nearly USD$5 billion worldwide.
If Cardiol is able to capture even a small part of that market, it will help them build a massive runway, driving revenue while trials are underway.
And if any of these trials show positive results, this could be a major catalyst for Cardiol’s shares to jump in the months ahead.
Now Is The Most Exciting Time
With preparations for clinical trials underway, Cardiol is gearing up for an exciting start to 2021.
The company anticipates enrolling patients for its COVID-19 treatment trial shortly, which is likely to be a significant catalyst.
They will be collaborating with the highly respected contract research organization, Worldwide Clinical Trials, throughout the process.
Worldwide has already conducted several COVID-19 trials, so they’re intimately familiar with the process.
They’re also the same organization used by Compass Pathways when they tested a revolutionary treatment for treatment-resistant depression.
After those trials showed positive results, their shares soared from their IPO price of USD$17 in September 2020… to nearly USD$50 by the end of the year.
Meanwhile, Cardiol is also gearing up with Shoppers Drug Mart for a commercial push across Canada with Cortalex.
All this while preparations are ongoing for their pipeline trials in acute myocarditis and chronic heart failure.
With all these pieces coming together at once, this is a pivotal time for Cardiol.
And many are feeling especially bullish on their chances because of the caliber of the Cardiol team.
Their executive team is led by professionals with decades of experience in cardiac medicine.
And they also have the privilege of working with Colin Stott, a member of their Board of Directors.
Stott has over 30 years of experience in the biotech industry, with specific expertise in this exciting space of cannabinoid-based medicine.
GET OUR SPECIAL REPORT ON CARDIOL’S REVOLUTIONARY TREATMENT AND HOW EARLY INVESTORS COULD PROFIT.
That’s because before serving as the COO of Alinova Biosciences…
He held several executive positions at GW Pharmaceuticals, which built a multi-billion dollar business in just a few years using cannabidiol as a treatment.
Now, Cardiol hopes to leverage his expertise and experience to help them match that success.
If all goes according to plan, Cardiol’s revolutionary treatment could be a game-changer, both for patients and investors.
Just 4 years ago, another small company, MyoKardia, began developing a treatment for a rare cardiac disease.
At that time, they were valued at around USD$200 million.
After reporting data for the first time, that valuation jumped to USD$2 billion.
The next time it was up to USD$6 billion.
In September, Bristol-Myers acquired them in a deal worth USD$13 billion.
Their valuation went from USD$200 million to USD$13 billion in under 4 years.
That’s the power of delivering an effective treatment for rare cardiac diseases.
Now, Cardiol is gearing up to become the next big biotech player in this corner of the market.
In a recent report by financial firm Raymond James, they reported, “We view each of Cardiol’s recent announcements as incrementally positive…
“And we believe the sum of this forward progress should lead to substantial clinical advances being made during the first half of 2021.”
With 3 promising treatment candidates and a commercial push throughout Canada, the coming months will be the most exciting time for Cardiol.
IMPORTANT NOTICE AND DISCLAIMER
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production of this piece by the company or companies mentioned above.